{
    "references": [
        {
            "bibentry": "Bottaro, DP, Rubin, JS, Faletto, DL, et al. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 1991; 251: 802–4. PMID: 1846706",
            "process_entry": "True",
            "doi": "10.1126/science.1846706",
            "pmid": "1846706",
            "xmlid": "CIT0001"
        },
        {
            "bibentry": "Bertotti, A, Comoglio, PM. Tyrosine kinase signal specificity: lessons from the HGF receptor. Trends Biochem Sci 2003; 28: 527–33. PMID: 14559181",
            "process_entry": "True",
            "doi": "10.1016/j.tibs.2003.09.001",
            "pmid": "14559181",
            "xmlid": "CIT0002"
        },
        {
            "bibentry": "Galimi, F, Brizzi, MF, Comoglio, PM. The hepatocyte growth factor and its receptor. Stem Cells Suppl 1996; 11: 22–30.",
            "process_entry": "True",
            "xmlid": "CIT0003"
        },
        {
            "bibentry": "Ponzetto, C, Bardelli, A, Zhen, Z, et al. A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. Cell 1994; 77: 261–71. PMID: 7513258",
            "process_entry": "True",
            "doi": "10.1016/0092-8674(94)90318-2",
            "pmid": "7513258",
            "xmlid": "CIT0004"
        },
        {
            "bibentry": "Furge, KA, Zhang, YW, Vande Woude, GF. Met receptor tyrosine kinase: enhanced signaling through adapter proteins. Oncogene 2000; 19: 5582–9. PMID: 11114738",
            "process_entry": "True",
            "doi": "10.1038/sj.onc.1203859",
            "pmid": "11114738",
            "xmlid": "CIT0005"
        },
        {
            "bibentry": "Trusolino, L, Comoglio, PM. Scatter-factor and semaphorin receptors: cell signalling for invasive growth. Nat Rev Cancer 2002; 2: 289–300. PMID: 12001990",
            "process_entry": "True",
            "doi": "10.1038/nrc779",
            "pmid": "12001990",
            "xmlid": "CIT0006"
        },
        {
            "bibentry": "Birchmeier, C, Birchmeier, W, Gherardi, E, et al. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003; 4: 915–25. PMID: 14685170",
            "process_entry": "True",
            "doi": "10.1038/nrm1261",
            "pmid": "14685170",
            "xmlid": "CIT0007"
        },
        {
            "bibentry": "Parikh, PK, Ghate, MD. Recent advances in the discovery of small molecule c-Met Kinase inhibitors. Eur J Med Chem 2018; 143: 1103–38. PMID: 29157685",
            "process_entry": "True",
            "doi": "10.1016/j.ejmech.2017.08.044",
            "pmid": "29157685",
            "xmlid": "CIT0008"
        },
        {
            "bibentry": "Trusolino, L, Bertotti, A, Comoglio, PM. MET signalling: principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol 2010; 11: 834–48. PMID: 21102609",
            "process_entry": "True",
            "doi": "10.1038/nrm3012",
            "pmid": "21102609",
            "xmlid": "CIT0009"
        },
        {
            "bibentry": "Chmielowiec, J, Borowiak, M, Morkel, M, et al. c-Met is essential for wound healing in the skin. J Cell Biol 2007; 177: 151–62. PMID: 17403932",
            "process_entry": "True",
            "doi": "10.1083/jcb.200701086",
            "pmid": "17403932",
            "pmcid": "PMC2064119",
            "xmlid": "CIT0010"
        },
        {
            "bibentry": "Lim, YC, Kang, HJ, Moon, JH. C-Met pathway promotes self-renewal and tumorigenecity of head and neck squamous cell carcinoma stem-like cell. Oral Oncol 2014; 50: 633–9. PMID: 24835851",
            "process_entry": "True",
            "doi": "10.1016/j.oraloncology.2014.04.004",
            "pmid": "24835851",
            "xmlid": "CIT0011"
        },
        {
            "bibentry": "Ruco, L, Scarpino, S. The pathogenetic role of the HGF/c-Met system in papillary carcinoma of the thyroid. Biomedicines 2014; 2: 263–74. PMID: 28548071",
            "process_entry": "True",
            "doi": "10.3390/biomedicines2040263",
            "pmid": "28548071",
            "pmcid": "PMC5344270",
            "xmlid": "CIT0012"
        },
        {
            "bibentry": "Bean, J, Brennan, C, Shih, JY, et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA 2007; 104: 20932–7. PMID: 18093943",
            "process_entry": "True",
            "doi": "10.1073/pnas.0710370104",
            "pmid": "18093943",
            "pmcid": "PMC2409244",
            "xmlid": "CIT0013"
        },
        {
            "bibentry": "Houldsworth, J, Cordon-Cardo, C, Ladanyi, M, et al. Gene amplification in gastric and esophageal adenocarcinomas. Cancer Res 1990; 50: 6417–22. PMID: 2400999",
            "process_entry": "True",
            "pmid": "2400999",
            "xmlid": "CIT0014"
        },
        {
            "bibentry": "Gunasinghe, NP, Wells, A, Thompson, EW, et al. Mesenchymal-epithelial transition (MET) as a mechanism for metastatic colonisation in breast cancer. Cancer Metastasis Rev 2012; 31: 469–78. PMID: 22729277",
            "process_entry": "True",
            "doi": "10.1007/s10555-012-9377-5",
            "pmid": "22729277",
            "xmlid": "CIT0015"
        },
        {
            "bibentry": "Tang, C, Jardim, DL, Falchook, GS, et al. MET nucleotide variations and amplification in advanced ovarian cancer: characteristics and outcomes with c-Met inhibitors. Oncoscience 2013; 1: 5–13. PMID: 25593979",
            "process_entry": "True",
            "doi": "10.18632/oncoscience.3",
            "pmid": "25593979",
            "pmcid": "PMC4295762",
            "xmlid": "CIT0016"
        },
        {
            "bibentry": "Delitto, D, Vertes, GE, Hughes, SJ, et al. c-Met signaling in the development of tumorigenesis and chemoresistance: potential applications in pancreatic cancer. World J Gastroenterol 2014; 20: 8458–70. PMID: 25024602",
            "process_entry": "True",
            "doi": "10.3748/wjg.v20.i26.8458",
            "pmid": "25024602",
            "pmcid": "PMC4093697",
            "xmlid": "CIT0017"
        },
        {
            "bibentry": "Humphrey, PA, Zhu, X, Zarnegar, R, et al. Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma. Am J Pathol 1995; 147: 386–96. PMID: 7639332",
            "process_entry": "True",
            "pmid": "7639332",
            "pmcid": "PMC1869824",
            "xmlid": "CIT0018"
        },
        {
            "bibentry": "Liu, Y, Yu, XF, Zou, J, et al. Prognostic value of c-Met in colorectal cancer: a meta-analysis. World J Gastroenterol 2015; 21: 3706–10. PMID: 25834339",
            "process_entry": "True",
            "doi": "10.3748/wjg.v21.i12.3706",
            "pmid": "25834339",
            "pmcid": "PMC4375596",
            "xmlid": "CIT0019"
        },
        {
            "bibentry": "Engelman, JA, Zejnullahu, K, Mitsudomi, T, et al. Met amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007; 316: 1039–43. PMID: 17463250",
            "process_entry": "True",
            "doi": "10.1126/science.1141478",
            "pmid": "17463250",
            "xmlid": "CIT0020"
        },
        {
            "bibentry": "Straussman, R, Morikawa, T, Shee, K, et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 2012; 487: 500–4. PMID: 22763439",
            "process_entry": "True",
            "doi": "10.1038/nature11183",
            "pmid": "22763439",
            "pmcid": "PMC3711467",
            "xmlid": "CIT0021"
        },
        {
            "bibentry": "Chan, AM, Rubin, JS, Bottaro, DP, et al. Identification of a competitive HGF antagonist encoded by an alternative transcript. Science 1991; 254: 1382–5. PMID: 1720571",
            "process_entry": "True",
            "doi": "10.1126/science.1720571",
            "pmid": "1720571",
            "xmlid": "CIT0022"
        },
        {
            "bibentry": "Michieli, P, Mazzone, M, Basilico, C, et al. Targeting the tumor and its microenvironment by a dual-function decoy Met receptor. Cancer Cell 2004; 6: 61–73. PMID: 15261142",
            "process_entry": "True",
            "doi": "10.1016/j.ccr.2004.05.032",
            "pmid": "15261142",
            "xmlid": "CIT0023"
        },
        {
            "bibentry": "Burgess, T, Coxon, A, Meyer, S, et al. Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potentialagainst hepatocyte growth factor/c-Met-dependent human tumors. Cancer Res 2006; 66: 1721–9. PMID: 16452232",
            "process_entry": "True",
            "doi": "10.1158/0008-5472.can-05-3329",
            "pmid": "16452232",
            "xmlid": "CIT0024"
        },
        {
            "bibentry": "Martens, T, Schmidt, NO, Eckerich, C, et al. A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo. Clin Cancer Res 2006; 12: 6144–52. PMID: 17062691",
            "process_entry": "True",
            "doi": "10.1158/1078-0432.ccr-05-1418",
            "pmid": "17062691",
            "xmlid": "CIT0025"
        },
        {
            "bibentry": "Ugolini, M, Kenigsberg, A, Rak, F, et al. Discovery, pharmacokinetic and pharmacological properties of the potent and selective MET kinase inhibitor, 1-{6-[6-(4-Fluoro-phenyl)-[1,2,4]triazolo[4,3-b]pyridazin-3-ylsulfanyl]-benzothiazol-2-yl}-3-(2-morpholin-4-yl-ethyl)-urea (SAR125844). J Med Chem 2016; 59: 7066–74. PMID: 27355974",
            "process_entry": "True",
            "doi": "10.1021/acs.jmedchem.6b00280",
            "pmid": "27355974",
            "xmlid": "CIT0026"
        },
        {
            "bibentry": "Tang, Q, Wang, L, Duan, Y, et al. Discovery of novel 7-azaindole derivatives bearing dihydropyridazine moiety as c-Met kinase inhibitors. Eur J Med Chem 2017; 133: 97–106. PMID: 28384549",
            "process_entry": "True",
            "doi": "10.1016/j.ejmech.2017.03.045",
            "pmid": "28384549",
            "xmlid": "CIT0027"
        },
        {
            "bibentry": "Zhang, L, Zhao, J, Zhang, B, et al. Discovery of [1,2,4]triazolo[3,4-b][1,3,4]thiadiazole derivatives as novel, potent and selective c-Met kinase inhibitors: Synthesis, SAR study, and biological activity. Eur J Med Chem 2018; 150: 809–16. PMID: 29602036",
            "process_entry": "True",
            "doi": "10.1016/j.ejmech.2018.03.049",
            "pmid": "29602036",
            "xmlid": "CIT0028"
        },
        {
            "bibentry": "Shi, L, Wu, TT, Wang, Z, et al. Discovery of quinazolin-4-amines bearing benzimidazole fragments as dual inhibitors of c-Met and VEGFR-2. Bioorg Med Chem 2014; 22: 4735–44. PMID: 25082515",
            "process_entry": "True",
            "doi": "10.1016/j.bmc.2014.07.008",
            "pmid": "25082515",
            "xmlid": "CIT0029"
        },
        {
            "bibentry": "Albrecht, BK, Harmange, JC, Bauer, D, et al. Discovery and optimization of triazolopyridazines as potent and selective inhibitors of the c-Met kinase. J Med Chem 2008; 51: 2879–82. PMID: 18426196",
            "process_entry": "True",
            "doi": "10.1021/jm800043g",
            "pmid": "18426196",
            "xmlid": "CIT0030"
        },
        {
            "bibentry": "Accelrys Software Inc. Discovery Studio Visualizer, Release 4.0. Accelrys Software Inc, San Diego, CA, USA, 2013.",
            "process_entry": "True",
            "xmlid": "CIT0031"
        }
    ],
    "localid": "MED-30422010",
    "doi": "10.1080/14756366.2018.1533822",
    "pmid": "10.1080/14756366.2018.1533822",
    "pmcid": "30422010",
    "curator": "BEE EuropeanPubMedCentralProcessor",
    "source_provider": "Europe PubMed Central",
    "source": "https://www.ebi.ac.uk/europepmc/webservices/rest/30422010/fullTextXML",
    "reference_pointers": [
        [
            {
                "n_rp": 0,
                "xref_id": "CIT0001",
                "rp_string": "1–3",
                "rp_xpath": "/article/body/sec[1]/p[1]/xref[1]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[1]),1,211)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 1,
                "xref_id": "CIT0004",
                "rp_string": "4–6",
                "rp_xpath": "/article/body/sec[1]/p[1]/xref[2]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[1]),337,257)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 2,
                "xref_id": "CIT0007",
                "rp_string": "7–10",
                "rp_xpath": "/article/body/sec[1]/p[2]/xref[1]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),1,262)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 3,
                "xref_id": "CIT0007",
                "rp_string": "7",
                "rp_xpath": "/article/body/sec[1]/p[2]/xref[2]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),264,88)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 4,
                "xref_id": "CIT0011",
                "rp_string": "11–19",
                "rp_xpath": "/article/body/sec[1]/p[2]/xref[3]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),353,356)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 5,
                "xref_id": "CIT0013",
                "rp_string": "13",
                "rp_xpath": "/article/body/sec[1]/p[2]/xref[4]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),710,158)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 6,
                "xref_id": "CIT0020",
                "rp_string": "20",
                "rp_xpath": "/article/body/sec[1]/p[2]/xref[5]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),710,158)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 7,
                "xref_id": "CIT0021",
                "rp_string": "21",
                "rp_xpath": "/article/body/sec[1]/p[2]/xref[6]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),710,158)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 8,
                "xref_id": "CIT0022",
                "rp_string": "22",
                "rp_xpath": "/article/body/sec[1]/p[3]/xref[1]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[3]),1,240)",
                "containers_title": [
                    "Introduction"
                ],
                "pl_string": "In the past few years, different strategies have been pursued to inhibit abnormal c-Met signalling pathway, including HGF and c-Met biological antagonists22,23, antibodies against HGF or c-Met24,25, and small-molecule c-Met inhibitors26–28. Among them, ATP-competitive small-molecule c-Met kinase inhibitor has obtained remarkable achievements within the pharmaceutical industry, leading to the marketing of crizotinib (1) and cabozantinib (5), and dozens of candidates currently under clinical trials, such as capmatinib (2), volitinib (3), AMG 337 (4), foretinib (6), and BMS 777607 (7) (Figure 1)8. All these small-molecule c-Met inhibitors can basically be categorised into two classes (classes I and II) according to their structures and binding modes with c-Met. Class I c-Met inhibitors (1–4) bind to the entrance of ATP-binding site in a U-shaped conformation around Met1211, while class II inhibitors (5–7) bind to c-Met in an extended conformation that stretches from the ATP-binding site to the deep hydrophobic pocket (Figure 2).",
                "pl_xpath": "/article/body/sec[1]/p[3]"
            },
            {
                "n_rp": 9,
                "xref_id": "CIT0023",
                "rp_string": "23",
                "rp_xpath": "/article/body/sec[1]/p[3]/xref[2]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[3]),1,240)",
                "containers_title": [
                    "Introduction"
                ],
                "pl_string": "In the past few years, different strategies have been pursued to inhibit abnormal c-Met signalling pathway, including HGF and c-Met biological antagonists22,23, antibodies against HGF or c-Met24,25, and small-molecule c-Met inhibitors26–28. Among them, ATP-competitive small-molecule c-Met kinase inhibitor has obtained remarkable achievements within the pharmaceutical industry, leading to the marketing of crizotinib (1) and cabozantinib (5), and dozens of candidates currently under clinical trials, such as capmatinib (2), volitinib (3), AMG 337 (4), foretinib (6), and BMS 777607 (7) (Figure 1)8. All these small-molecule c-Met inhibitors can basically be categorised into two classes (classes I and II) according to their structures and binding modes with c-Met. Class I c-Met inhibitors (1–4) bind to the entrance of ATP-binding site in a U-shaped conformation around Met1211, while class II inhibitors (5–7) bind to c-Met in an extended conformation that stretches from the ATP-binding site to the deep hydrophobic pocket (Figure 2).",
                "pl_xpath": "/article/body/sec[1]/p[3]"
            },
            {
                "n_rp": 10,
                "xref_id": "CIT0024",
                "rp_string": "24",
                "rp_xpath": "/article/body/sec[1]/p[3]/xref[3]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[3]),1,240)",
                "containers_title": [
                    "Introduction"
                ],
                "pl_string": "In the past few years, different strategies have been pursued to inhibit abnormal c-Met signalling pathway, including HGF and c-Met biological antagonists22,23, antibodies against HGF or c-Met24,25, and small-molecule c-Met inhibitors26–28. Among them, ATP-competitive small-molecule c-Met kinase inhibitor has obtained remarkable achievements within the pharmaceutical industry, leading to the marketing of crizotinib (1) and cabozantinib (5), and dozens of candidates currently under clinical trials, such as capmatinib (2), volitinib (3), AMG 337 (4), foretinib (6), and BMS 777607 (7) (Figure 1)8. All these small-molecule c-Met inhibitors can basically be categorised into two classes (classes I and II) according to their structures and binding modes with c-Met. Class I c-Met inhibitors (1–4) bind to the entrance of ATP-binding site in a U-shaped conformation around Met1211, while class II inhibitors (5–7) bind to c-Met in an extended conformation that stretches from the ATP-binding site to the deep hydrophobic pocket (Figure 2).",
                "pl_xpath": "/article/body/sec[1]/p[3]"
            },
            {
                "n_rp": 11,
                "xref_id": "CIT0025",
                "rp_string": "25",
                "rp_xpath": "/article/body/sec[1]/p[3]/xref[4]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[3]),1,240)",
                "containers_title": [
                    "Introduction"
                ],
                "pl_string": "In the past few years, different strategies have been pursued to inhibit abnormal c-Met signalling pathway, including HGF and c-Met biological antagonists22,23, antibodies against HGF or c-Met24,25, and small-molecule c-Met inhibitors26–28. Among them, ATP-competitive small-molecule c-Met kinase inhibitor has obtained remarkable achievements within the pharmaceutical industry, leading to the marketing of crizotinib (1) and cabozantinib (5), and dozens of candidates currently under clinical trials, such as capmatinib (2), volitinib (3), AMG 337 (4), foretinib (6), and BMS 777607 (7) (Figure 1)8. All these small-molecule c-Met inhibitors can basically be categorised into two classes (classes I and II) according to their structures and binding modes with c-Met. Class I c-Met inhibitors (1–4) bind to the entrance of ATP-binding site in a U-shaped conformation around Met1211, while class II inhibitors (5–7) bind to c-Met in an extended conformation that stretches from the ATP-binding site to the deep hydrophobic pocket (Figure 2).",
                "pl_xpath": "/article/body/sec[1]/p[3]"
            },
            {
                "n_rp": 12,
                "xref_id": "CIT0026",
                "rp_string": "26–28",
                "rp_xpath": "/article/body/sec[1]/p[3]/xref[5]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[3]),1,240)",
                "containers_title": [
                    "Introduction"
                ],
                "pl_string": "In the past few years, different strategies have been pursued to inhibit abnormal c-Met signalling pathway, including HGF and c-Met biological antagonists22,23, antibodies against HGF or c-Met24,25, and small-molecule c-Met inhibitors26–28. Among them, ATP-competitive small-molecule c-Met kinase inhibitor has obtained remarkable achievements within the pharmaceutical industry, leading to the marketing of crizotinib (1) and cabozantinib (5), and dozens of candidates currently under clinical trials, such as capmatinib (2), volitinib (3), AMG 337 (4), foretinib (6), and BMS 777607 (7) (Figure 1)8. All these small-molecule c-Met inhibitors can basically be categorised into two classes (classes I and II) according to their structures and binding modes with c-Met. Class I c-Met inhibitors (1–4) bind to the entrance of ATP-binding site in a U-shaped conformation around Met1211, while class II inhibitors (5–7) bind to c-Met in an extended conformation that stretches from the ATP-binding site to the deep hydrophobic pocket (Figure 2).",
                "pl_xpath": "/article/body/sec[1]/p[3]"
            }
        ],
        [
            {
                "n_rp": 13,
                "xref_id": "CIT0008",
                "rp_string": "8",
                "rp_xpath": "/article/body/sec[1]/p[3]/xref[7]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[3]),242,360)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 14,
                "xref_id": "CIT0029",
                "rp_string": "29",
                "rp_xpath": "/article/body/sec[1]/p[4]/xref[1]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[4]),1,150)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 15,
                "xref_id": "CIT0029",
                "rp_string": "29",
                "rp_xpath": "/article/body/sec[2]/sec[1]/sec[1]/p/xref",
                "context_xpath": "substring(string(/article/body/sec[2]/sec[1]/sec[1]/p),1,268)",
                "containers_title": [
                    "Experimental",
                    "Chemistry",
                    "General procedure for the preparation of the 5-nitro-2-phenyl-1H-benzo[d]imidazole derivatives (10a-s)"
                ]
            }
        ],
        [
            {
                "n_rp": 16,
                "xref_id": "CIT0029",
                "rp_string": "29",
                "rp_xpath": "/article/body/sec[2]/sec[1]/sec[2]/p[1]/xref",
                "context_xpath": "substring(string(/article/body/sec[2]/sec[1]/sec[2]/p[1]),1,98)",
                "containers_title": [
                    "Experimental",
                    "Chemistry",
                    "General procedure for the preparation of the 2-phenyl-1H-benzo[d]imidazol-5-amine derivatives (11a-s)"
                ]
            }
        ],
        [
            {
                "n_rp": 17,
                "xref_id": "CIT0030",
                "rp_string": "30",
                "rp_xpath": "/article/body/sec[2]/sec[4]/p/xref[1]",
                "context_xpath": "substring(string(/article/body/sec[2]/sec[4]/p),1,260)",
                "containers_title": [
                    "Experimental",
                    "Molecular docking"
                ]
            }
        ],
        [
            {
                "n_rp": 18,
                "xref_id": "CIT0029",
                "rp_string": "29",
                "rp_xpath": "/article/body/sec[3]/sec[1]/p/xref[2]",
                "context_xpath": "substring(string(/article/body/sec[3]/sec[1]/p),1,187)",
                "containers_title": [
                    "Results and discussion",
                    "Chemistry"
                ]
            }
        ]
    ]
}